Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Schizophr Res ; 204: 295-303, 2019 02.
Artigo em Inglês | MEDLINE | ID: mdl-30241990

RESUMO

Omega-3 treatment studies for multi-episode schizophrenia or clinical high risk for conversion to psychosis states have had variable, and often negative, results. To examine adjunctive omega-3 treatment for recent onset psychosis, participants aged 15-40 years with recent onset schizophrenia-spectrum (n = 46) or bipolar (n = 4) disorders and current psychotic symptoms were treated for 16 weeks with risperidone and randomly-assigned omega-3 (EPA 740 mg and DHA 400 mg daily) or matching placebo. The primary outcome measure was the Brief Psychiatric Rating Scale (BPRS) total score. Mean lifetime antipsychotic exposure was 18.1 days. Length of time in treatment, risperidone dose and number of omega-3/placebo capsules taken did not differ between conditions. Longitudinal analysis of the total BPRS score revealed a trend level (p = 0.0826) treatment effect favoring omega-3 treatment. Lorazepam was an allowed concomitant medication. Among the subgroup (N = 23) who did not receive lorazepam, the treatment effect on BPRS total scores favoring omega-3 was significant (p = 0.0406) and factor scores analyses revealed a substantial decrease in depression-anxiety with omega-3 but no change with placebo (treatment-by-time interaction, p = 0.0184). Motor side effects did not differ between conditions. Analysis of Systematic Assessment for Treatment Emergent Events assessments revealed fewer adverse events overall with omega-3 compared with placebo with the largest differences between conditions (all favoring omega-3) on confusion, anxiety, depression, irritability, and tiredness/fatigue. These results suggest that omega-3 adjuvant treatment is a potential option for depression and anxiety symptoms of people with recent onset psychosis. Further research is needed to confirm this potential. Clinical trial registration: NCT01786239.


Assuntos
Antipsicóticos/farmacologia , Ansiedade/tratamento farmacológico , Transtorno Bipolar/tratamento farmacológico , Depressão/tratamento farmacológico , Ácidos Graxos Ômega-3/farmacologia , Transtornos Psicóticos/tratamento farmacológico , Risperidona/farmacologia , Esquizofrenia/tratamento farmacológico , Adolescente , Adulto , Antipsicóticos/administração & dosagem , Ansiedade/etiologia , Transtorno Bipolar/complicações , Escalas de Graduação Psiquiátrica Breve , Depressão/etiologia , Quimioterapia Combinada , Ácidos Graxos Ômega-3/administração & dosagem , Feminino , Humanos , Masculino , Avaliação de Resultados em Cuidados de Saúde , Transtornos Psicóticos/complicações , Risperidona/administração & dosagem , Esquizofrenia/complicações , Adulto Jovem
2.
Schizophr Bull ; 41(6): 1227-36, 2015 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-26338693

RESUMO

Research findings are particularly important for medication choice for first-episode patients as individual prior medication response to guide treatment decisions is unavailable. We describe the first large-scale double-masked randomized comparison with first-episode patients of aripiprazole and risperidone, 2 commonly used first-episode treatment agents. One hundred ninety-eight participants aged 15-40 years with schizophrenia, schizophreniform disorder, schizoaffective disorder or psychotic disorder Not Otherwise Specified, and who had been treated in their lifetime with antipsychotics for 2 weeks or less were randomly assigned to double-masked aripiprazole (5-30 mg/d) or risperidone (1-6 mg/d) and followed for 12 weeks. Positive symptom response rates did not differ (62.8% vs 56.8%) nor did time to response. Aripiprazole-treated participants had better negative symptom outcomes but experienced more akathisia. Body mass index change did not differ between treatments but advantages were found for aripiprazole treatment for total and low-density lipoprotein cholesterol, fasting glucose, and prolactin levels. Post hoc analyses suggested advantages for aripiprazole on depressed mood. Overall, if the potential for akathisia is a concern, low-dose risperidone as used in this trial maybe a preferred choice over aripiprazole. Otherwise, aripiprazole would be the preferred choice over risperidone in most situations based upon metabolic outcome advantages and some symptom advantages within the context of similar positive symptom response between medications.


Assuntos
Antipsicóticos/farmacologia , Aripiprazol/farmacologia , Avaliação de Resultados em Cuidados de Saúde , Transtornos Psicóticos/tratamento farmacológico , Risperidona/farmacologia , Esquizofrenia/tratamento farmacológico , Adolescente , Adulto , Antipsicóticos/administração & dosagem , Antipsicóticos/efeitos adversos , Aripiprazol/administração & dosagem , Aripiprazol/efeitos adversos , Método Duplo-Cego , Feminino , Humanos , Masculino , Risperidona/administração & dosagem , Risperidona/efeitos adversos , Adulto Jovem
3.
Clin Psychol Psychother ; 17(1): 44-50, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-19701959

RESUMO

The Schwartz Outcome Scale-10 (SOS-10) is a 10-item questionnaire that measures the broad domain of psychological well-being and quality of life. The SOS-10 is easy to administer and score. Past research has shown its utility, reliability and validity in different clinical settings (i.e., inpatient, outpatient and non-psychiatry medical settings) and with diverse clinical populations in measuring treatment outcome. The present study looks to extend the construct validity of the SOS-10 to assessing quality of life and psychological health in non-clinical samples as well. The results reveal that the SOS-10 is associated in predicted ways with established measures of attachment, interpersonal distress, alexithymia and the big five model whose construct validity and psychometric soundness has been well documented. The SOS-10 was also associated in predicted ways with ratings of childhood memories and the length of the participants' longest romantic relationship.


Assuntos
Sintomas Afetivos/diagnóstico , Sintomas Afetivos/psicologia , Relações Interpessoais , Amor , Memória , Apego ao Objeto , Qualidade de Vida/psicologia , Inquéritos e Questionários , Criança , Feminino , Humanos , Masculino , Reprodutibilidade dos Testes , Índice de Gravidade de Doença , Fatores de Tempo , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...